細胞株および細胞膜の世界市場

世界の細胞株および細胞膜の市場規模は、2024年の57億米ドル、2025年の63億米ドルから、2025年から2030年までの予測期間中はCAGR 12.5%で推移し、2030年には114億米ドルに達すると予測されています。

北米市場は2024年の30億米ドル、2025年の33億米ドルから、2025年から2030年までの予測期間中はCAGR 12.4%で推移し、2030年には59億米ドルに達すると予測されています。アジア太平洋市場は、2024年の9億8,880万米ドル、2025年の11億米ドルから、CAGR 14.3%で推移し、2030年には22億米ドルに達すると予測されています。

当レポートでは、世界の細胞株および細胞膜の市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、新興技術および技術開発の動向、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

• 市場見通し
• 調査範囲
• 市場サマリー
• 市場成長要因
• 新興技術
• セグメント分析
• 地域分析
• 総論

第2章 市場概要

• 概要・市場の定義
• 技術的背景
• 細胞株と細胞培養の開発
• サプライチェーン分析
• 原材料の調達
• 製造・開発プロセス
• エンドユーザー
• ポーターのファイブフォース分析
• PESTEL分析
• 戦略的提言

第3章 市場力学

• 概要
• 市場促進要因
• 細胞株のスケールアップを加速する技術の進歩
• 製薬企業とバイオテクノロジー企業による医薬品開発への投資増加
• 細胞ベースアッセイにおける細胞株技術の採用増加
• 細胞培養ワクチンの需要増加
• 市場抑制要因
• 細胞生物学研究の高コスト性
• 技術を有する専門家の不足
• 市場機会
• モノクローナル抗体の承認件数の増加
• 細胞治療・再生医療の拡大

第4章 規制状況

• 細胞株および細胞膜市場における規制と基準
• 米国
• EU
• 中国
• インド
• 日本
• ブラジル

第5章 新興技術と新たな開発

• 新興技術
• 遺伝子編集
• オートメーション
• ハイスループットスクリーニング

第6章 市場セグメンテーション分析

• セグメンテーションの内訳
• 市場内訳：製品別
• 重要ポイント
• 細胞株
• 細胞膜
• 市場内訳：情報源別
• 重要ポイント
• 哺乳類細胞株
• 非哺乳類細胞株
• 市場内訳：用途別
• 重要ポイント
• 基礎研究
• バイオ医薬品製造
• 創薬
• 毒性試験
• 組織工学
• その他
• 市場内訳：エンドユーザー別
• 重要ポイント
• バイオテクノロジーおよび製薬会社
• 学術研究機関
• その他
• 地理的内訳
• 市場内訳：地域別
• 重要ポイント
• 北米
• 欧州
• アジア太平洋
• その他の地域

第7章 競合情報

• 重要ポイント
• 主要企業ランキング
• 戦略分析
• 協定、協力、パートナーシップ
• 新製品の発売
• M&A
• 拡張
• その他

第8章 細胞株および細胞膜市場における持続可能性：ESGの観点

• 細胞株および細胞膜市場における持続可能性
• ESGリスク評価：データの理解
• ESGパフォーマンス分析
• 環境パフォーマンス
• 社会的パフォーマンス
• ガバナンスパフォーマンス
• 結論

第9章 付録

• 調査手法
• 略語
• 参考文献
• 企業プロファイル
• AGC BIOLOGICS
• ATCC
• CATALENT INC.
• CELL BIOLABS INC.
• CREATIVE BIOLABS
• CROWN BIOSCIENCE
• FUJIFILM CELLULAR DYNAMICS INC.
• IXCELLS BIOTECHNOLOGIES
• KBI BIOPHARMA
• LONZA
• MILTENYI BIOTEC
• PROMEGA CORP.
• PROMOCELL GMBH
• PROBIOGEN AG
• THERMO FISHER SCIENTIFIC INC.

List of Tables

• Summary Table : Global Market for Cell Lines and Membranes, by Region, Through 2030
• Table 1 : Key Sources and Description of Biological Contamination of Cell Lines and Membranes
• Table 2 : Key Mammalian and Insect Cell Cultures
• Table 3 : Animal Cell Lines Used in Research
• Table 4 : Cell Lines in the Drug Development Process, by Application
• Table 5 : Top 15 Biopharmaceutical Companies, by Research and Development Spending, 2023 and 2024
• Table 6 : Therapeutic Area Distribution of Approved Antibody Drugs, Through October 2023
• Table 7 : Global Market for Cell Lines and Membranes, by Product, Through 2030
• Table 8 : Global Market for Cell Lines, by Region, Through 2030
• Table 9 : NCI-60 Cancer Cell Lines
• Table 10 : U.S. Cancer Research Grants, by Cancer Type, as of February 2025
• Table 11 : Global Market for Cancer Cell Lines, by Region, Through 2030
• Table 12 : Global Market for Immunotherapy Cell Lines, by Region, Through 2030
• Table 13 : Global Market for Ion Channel Cell Lines, by Region, Through 2030
• Table 14 : Global Market for Cell Signaling Pathway Cell Lines, by Region, Through 2030
• Table 15 : Global Market for GPCR Cell Lines, by Region, Through 2030
• Table 16 : Global Market for Gene Knockout Cell Lines, by Region, Through 2030
• Table 17 : Global Market for Other Cell Lines, by Region, Through 2030
• Table 18 : Global Market for Cell Membranes, by Region, Through 2030
• Table 19 : Global Market for Cell Lines, by Source, Through 2030
• Table 20 : Global Market for Mammalian Cell Lines, by Region, Through 2030
• Table 21 : Global Market for Non-Mammalian Cell Lines, by Region, Through 2030
• Table 22 : Global Market for Cell Lines and Membranes, by Application, Through 2030
• Table 23 : Global Cell Line and Membrane Market for Basic Research, by Region, Through 2030
• Table 24 : Therapeutic Area Distribution of Approved Antibody Drugs, Through October 2023
• Table 25 : Comparison of Human Cell Lines with Other Expression Systems in the Production of Therapeutic Proteins
• Table 26 : Global Cell Line and Membrane Market for Biopharmaceutical Production, by Region, Through 2030
• Table 27 : Global Cell Line and Membrane Market for Drug Discovery, by Region, Through 2030
• Table 28 : Global Cell Line and Membrane Market for Toxicity Testing, by Region, Through 2030
• Table 29 : Cell Lines Used in Tissue Engineering
• Table 30 : Global Cell Line and Membrane Market for Tissue Engineering, by Region, Through 2030
• Table 31 : Global Cell Line and Membrane Market for Other Applications, by Region, Through 2030
• Table 32 : Global Market for Cell Lines and Membranes, by End User, Through 2030
• Table 33 : Cell Lines Used in the Production of Biopharmaceuticals
• Table 34 : Global Cell Line and Membrane Market for Biotechnology and Pharmaceutical Companies, by Region, Through 2030
• Table 35 : Global Cell Line and Membrane Market for Academic Research and Institutes, by Region, Through 2030
• Table 36 : Global Cell Line and Membrane Market for Other End Users, by Region, Through 2030
• Table 37 : Global Market for Cell Lines and Membranes, by Region, Through 2030
• Table 38 : North American Market for Cell Lines and Membranes, by Product, Through 2030
• Table 39 : North American Market for Cell Lines and Membranes, by Type, Through 2030
• Table 40 : North American Market for Cell Lines and Membranes, by Source, Through 2030
• Table 41 : North American Market for Cell Lines and Membranes, by Application, Through 2030
• Table 42 : North American Market for Cell Lines and Membranes, by End User, Through 2030
• Table 43 : North American Market for Cell Lines and Membranes, by Country, Through 2030
• Table 44 : Estimated Incidence of Cancer Cases in the EU-27, by Country, 2022
• Table 45 : E.U. Therapeutic Monoclonal Antibodies Approved or in Review, 2023 and 2024
• Table 46 : European Market for Cell Lines and Membranes, by Product, Through 2030
• Table 47 : European Market for Cell Lines and Membranes, by Type, Through 2030
• Table 48 : European Market for Cell Lines and Membranes, by Source, Through 2030
• Table 49 : European Market for Cell Lines and Membranes, by Application, Through 2030
• Table 50 : European Market for Cell Lines and Membranes, by End User, Through 2030
• Table 51 : European Market for Cell Lines and Membranes, by Country, Through 2030
• Table 52 : Asia-Pacific Market for Cell Lines and Membranes, by Product, Through 2030
• Table 53 : Asia-Pacific Market for Cell Lines and Membranes, by Type, Through 2030
• Table 54 : Asia-Pacific Market for Cell Lines and Membranes, by Source, Through 2030
• Table 55 : Asia-Pacific Market for Cell Lines and Membranes, by Application, Through 2030
• Table 56 : Asia-Pacific Market for Cell Lines and Membranes, by End User, Through 2030
• Table 57 : Asia-Pacific Market for Cell Lines and Membranes, by Country, Through 2030
• Table 58 : RoW Market for Cell Lines and Membranes, by Product, Through 2030
• Table 59 : RoW Market for Cell Lines and Membranes, by Type, Through 2030
• Table 60 : RoW Market for Cell Lines and Membranes, by Source, Through 2030
• Table 61 : RoW Market for Cell Lines and Membranes, by Application, Through 2030
• Table 62 : RoW Market for Cell Lines and Membranes, by End User, Through 2030
• Table 63 : RoW Market for Cell Lines and Membranes, by Sub-Region, Through 2030
• Table 64 : Top Players Ranking in the Global Cell Line and Membrane Market, 2024
• Table 65 : Agreements, Collaborations and Partnerships in the Cell Line and Membrane Market, 2023-2025
• Table 66 : New Product Launches in the Cell Line and Membrane Market, 2023 and 2024
• Table 67 : Mergers and Acquisitions in the Cell Line and Membrane Market, 2023-2025
• Table 68 : Expansion Strategies in the Cell Line and Membrane Market, 2022-2025
• Table 69 : Other Competitive Strategies in the Cell Line and Membrane Market, 2022-2024
• Table 70 : Key Focus Areas in ESG Metrics
• Table 71 : ESG Rankings for Major Cell Line and Membrane Companies, as of December 2024
• Table 72 : ESG: Environmental Overview
• Table 73 : ESG: Social Factors Overview
• Table 74 : ESG: Governance Overview
• Table 75 : Abbreviations Used in this Report
• Table 76 : AGC Biologics: Company Snapshot
• Table 77 : AGC Biologics: Product Portfolio
• Table 78 : AGC Biologics: News/Key Developments, 2023 and 2024
• Table 79 : ATCC: Company Snapshot
• Table 80 : ATCC: Product Portfolio
• Table 81 : ATCC: News/Key Developments, 2023 and 2024
• Table 82 : Catalent Inc.: Company Snapshot
• Table 83 : Catalent Inc.: Financial Performance, FY 2022 and 2023
• Table 84 : Catalent Inc.: Product Portfolio
• Table 85 : Catalent Inc.: News/Key Developments, 2024 and 2025
• Table 86 : Cell Biolabs Inc.: Company Snapshot
• Table 87 : Cell Biolabs Inc.: Product Portfolio
• Table 88 : Creative Biolabs: Company Snapshot
• Table 89 : Creative Biolabs: Product Portfolio
• Table 90 : Creative Biolabs: News/Key Developments, 2025
• Table 91 : Crown Bioscience: Company Snapshot
• Table 92 : Crown Bioscience: Product Portfolio
• Table 93 : Crown Bioscience: News/Key Developments, 2024 and 2025
• Table 94 : Fujifilm Cellular Dynamics Inc.: Company Snapshot
• Table 95 : Fujifilm Cellular Dynamics Inc.: Product Portfolio
• Table 96 : Fujifilm Cellular Dynamics Inc.: News/Key Developments, 2022-2024
• Table 97 : iXCells Biotechnologies: Company Snapshot
• Table 98 : iXCells Biotechnologies: Product Portfolio
• Table 99 : iXCells Biotechnologies: News/Key Developments, 2024
• Table 100 : KBI Biopharma: Company Snapshot
• Table 101 : KBI Biopharma: Product Portfolio
• Table 102 : KBI Biopharma: News/Key Developments, 2022 and 2023
• Table 103 : Lonza: Company Snapshot
• Table 104 : Lonza: Financial Performance, FY 2023 and 2024
• Table 105 : Lonza: Product Portfolio
• Table 106 : Lonza: News/Key Developments, 2023
• Table 107 : Miltenyi Biotec: Company Snapshot
• Table 108 : Miltenyi Biotec: Product Portfolio
• Table 109 : Miltenyi Biotec: News/Key Developments, 2023 and 2024
• Table 110 : Promega Corp.: Company Snapshot
• Table 111 : Promega Corp.: Product Portfolio
• Table 112 : Promega Corp.: News/Key Developments, 2023 and 2024
• Table 113 : PromoCell GmbH: Company Snapshot
• Table 114 : PromoCell GmbH.: Product Portfolio
• Table 115 : ProBioGen AG: Company Snapshot
• Table 116 : ProBioGen AG: Product Portfolio
• Table 117 : ProBioGen AG: News/Key Developments, 2023-2025
• Table 118 : Thermo Fisher Scientific Inc.: Company Snapshot
• Table 119 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
• Table 120 : Thermo Fisher Scientific Inc.: Product Portfolio

List of Figures

• Summary Figure : Global Cell Line and Membrane Market Shares, by Region, 2024
• Figure 1 : Cell Line Selection Characteristics
• Figure 2 : Supply Chain of the Cell Line and Membrane Market
• Figure 3 : Cell Line Development Flow Chart
• Figure 4 : Porter's Five Forces Analysis: Cell Line and Membrane Market
• Figure 5 : PESTEL Analysis: Cell Line and Membrane Market
• Figure 6 : Strategic Recommendations: Cell Line and Membrane Market
• Figure 7 : Market Dynamics of Cell Line and Membrane
• Figure 8 : Emerging Technologies in the Cell Line and Membrane Market
• Figure 9 : Global Cell Line and Membrane Market Shares, by Product, 2024
• Figure 10 : Global Cell Line Market Shares, by Product, 2024
• Figure 11 : Process of Growing Cell Lines and Delivering to Patients
• Figure 12 : Production Process of Ion Channel Cell Line
• Figure 13 : Cell Signaling Pathway Cell Lines, by Application
• Figure 14 : GPCR Cell Line Development Process
• Figure 15 : Gene Knockout Cell Line Development Process
• Figure 16 : Global Cell Membrane Market Shares, by Region, 2024
• Figure 17 : Global Cell Line Market Shares, by Source, 2024
• Figure 18 : Global Cell Line and Membrane Market Shares, by Application, 2024
• Figure 19 : Cell Line and Membrane in Drug Discovery and Development Process, by Application
• Figure 20 : Global Cell Line and Membrane Market Shares, by End User, 2024
• Figure 21 : Biopharmaceutical Production Using Mammalian Cells
• Figure 22 : Cell Lines and Membranes Application in Academic and Research Institutes
• Figure 23 : Global Market Shares of Cell Line and Membrane, by Region, 2024
• Figure 24 : North American Market Shares of Cell Lines and Membranes, by Country, 2024
• Figure 25 : U.S. Elderly* Population, 2010-2050
• Figure 26 : European Market Shares of Cell Lines and Membranes, by Country, 2024
• Figure 27 : Asia-Pacific Market Shares of Cell Lines and Membranes, by Country, 2024
• Figure 28 : RoW Market Shares of Cell Lines and Membranes, by Sub-Region, 2024
• Figure 29 : Catalent Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 30 : Catalent Inc.: Revenue Share, by Region/Country, FY 2023
• Figure 31 : Lonza: Revenue Share, by Business Unit, FY 2024
• Figure 32 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 33 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2024

The global market for cell lines and membranes was valued at $5.7 billion in 2024 and is estimated to increase from $6.3 billion in 2025 to reach $11.4 billion by 2030, at a compound annual growth rate (CAGR) of 12.5% from 2025 through 2030.

The North American market for cell lines and membranes was valued at $3.0 billion in 2024 and is estimated to increase from $3.3 billion in 2025 to reach $5.9 billion by 2030, at a CAGR of 12.4% from 2025 through 2030.

The Asia-Pacific market for cell lines and membranes was valued at $988.8 million in 2024 and is estimated to increase from $1.1 billion in 2025 to reach $2.2 billion by 2030, at a CAGR of 14.3% from 2025 through 2030.

Report Scope

This report provides an overview of the global cell line and membrane market and analyzes market trends. It includes global revenue ($ millions) for base year data 2024, estimated data for 2025 and forecast data from 2026 to 2030. The market is segmented based on product types, subtypes, applications, end users and regions. The regions covered in this study are North America, Europe, Asia-Pacific and the Rest of the World (RoW), focusing on major countries within these regions.

The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It analyzes environmental, social and corporate governance (ESG) developments and discusses emerging technologies related to the market.

The report concludes with an analysis of the competitive landscape, which provides the ranking/share of key players in the global cell line and membrane market. It also has a dedicated section of company profiles that covers such details as overview, key financials, product portfolio and recent developments of key market players.

Report Includes

• 54 data tables and 67 additional tables
• An overview of the global market for cell lines and membranes
• An analysis of the global market trends, with market revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
• Discussion of the current and future market potential, and quantification of the market by product type, source, end use industry, application, and geographic region
• Identification of applications of cell lines in drug development, diagnostics, and molecular biology
• Description of advances in cell lines for cancer-based therapies
• Details about CAR-T cell and immune check point inhibitor therapy
• Comparison of the manufacturing processes for autologous and allogenic cells
• Explanation of the increasing adoption of cell line technologies in cell-based assay and the surging demand of antibody production
• Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, and ESG trends of the market
• Analysis of the key companies' market shares and proprietary technologies, strategic alliances, and patent portfolios
• Company profiles of major players within the industry, including ATCC, Catalent Inc., Lonza, and Thermo Fisher Scientific Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview and Market Definition
• Technology Background
• Development of Cell Lines and Cell Culture
• Supply Chain Analysis
• Procurement of Raw Materials
• Manufacturing and Development Process
• End Users
• Porter's Five Forces Analysis
• Threat of New Entrants: Medium
• Bargaining Power of Suppliers: Medium
• Bargaining Power of Buyers: Medium
• Threat of Substitute: Medium
• Industry Rivalry: High
• PESTEL Analysis
• Political
• Economical
• Social
• Technological
• Environmental
• Legal
• Strategic Recommendations

Chapter 3 Market Dynamics

• Overview
• Market Drivers
• Advances in Technologies Accelerating the Scale-Up of Cell Lines
• Rising Investments by Pharmaceutical and Biotechnology Companies in Drug Development
• Increasing Adoption of Cell Line Technologies in Cell-Based Assays
• Growing Demand for Cell Culture-Based Vaccines
• Market Restraints
• High Cost of Cell Biology Research
• Shortage of Skilled Professionals
• Market Opportunities
• Increasing Number of Approvals for Monoclonal Antibody Types
• Expansion of Cell Therapy and Regenerative Medicine

Chapter 4 Regulatory Landscape

• Regulations and Standards in Cell Line and Membrane Market
• U.S.
• European Union
• China
• India
• Japan
• Brazil

Chapter 5 Emerging Technologies and New Developments

• Emerging Technologies
• Gene Editing
• Automation
• High-Throughput Screening

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Breakdown by Product
• Key Takeaways
• Cell Lines
• Cell Membrane
• Market Breakdown by Source
• Key Takeaways
• Mammalian Cell Lines
• Non-Mammalian Cell Lines
• Market Breakdown by Application
• Key Takeaways
• Basic Research
• Biopharmaceutical Production
• Drug Discovery
• Toxicity Testing
• Tissue Engineering
• Others
• Market Breakdown by End User
• Key Takeaways
• Biotechnology and Pharmaceutical Companies
• Academic and Research Institutes
• Other End Users
• Geographic Breakdown
• Market Breakdown by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Key Takeaways
• Top Players Ranking, 2024
• Strategic Analysis
• Agreements, Collaborations and Partnerships
• New Product Launches
• Mergers and Acquisitions
• Expansions
• Other Strategic Alliances

Chapter 8 Sustainability in the Cell Line and Membrane Market: ESG Perspective

• Sustainability in the Cell Line and Membrane Market
• ESG Risk Ratings: Understanding the Data
• ESG Performance Analysis
• Environmental Performance
• Social Performance
• Governance Performance
• Concluding Remarks

Chapter 9 Appendix

• Methodology
• Abbreviations
• References
• Company Profiles
• AGC BIOLOGICS
• ATCC
• CATALENT INC.
• CELL BIOLABS INC.
• CREATIVE BIOLABS
• CROWN BIOSCIENCE
• FUJIFILM CELLULAR DYNAMICS INC.
• IXCELLS BIOTECHNOLOGIES
• KBI BIOPHARMA
• LONZA
• MILTENYI BIOTEC
• PROMEGA CORP.
• PROMOCELL GMBH
• PROBIOGEN AG
• THERMO FISHER SCIENTIFIC INC.